Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page displays Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer build of the page's interface without changes to the study information.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s displayed software release/revision indicator was updated from v3.5.2 to v3.5.3, reflecting a website version change rather than any modification to the study record.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No visible content or functionality changes.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision tag updated to v3.5.0, replacing the previous v3.4.3. No study content or results are impacted.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check99 days agoChange DetectedThe page shows a new site revision note (Revision: v3.4.2) and removes an older funding-status warning and Revision: v3.4.1; these are maintenance updates rather than changes to the trial details or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.